[{"id":"3459cfe0-8df3-41ce-b99a-ba11d3ea3232","acronym":"EVEREST-2","url":"https://clinicaltrials.gov/study/NCT06051695","created_at":"2023-09-25T14:10:18.366Z","updated_at":"2024-07-02T16:34:59.359Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","source_id_and_acronym":"NCT06051695 - EVEREST-2","lead_sponsor":"A2 Biotherapeutics Inc.","biomarkers":" HLA-A • MSLN","pipe":" | ","alterations":" MSLN expression • HLA-A*02","tags":["HLA-A • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • HLA-A*02"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 04/03/2024","start_date":" 04/03/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2024-06-04"},{"id":"67a7cc8f-4495-4593-a5ec-9a4e0b7286d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02414269","created_at":"2021-01-18T11:32:05.371Z","updated_at":"2024-07-02T16:35:02.997Z","phase":"Phase 1/2","brief_title":"Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin","source_id_and_acronym":"NCT02414269","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PD-L1 • MSLN","pipe":" | ","alterations":" MSLN expression","tags":["PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • cyclophosphamide intravenous • iCasp9M28z T cell infusion"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-05-17"},{"id":"1feb857d-51e5-4682-a570-aafec2b08650","acronym":"","url":"https://clinicaltrials.gov/study/NCT05568680","created_at":"2022-10-06T14:56:16.043Z","updated_at":"2024-07-02T16:35:03.301Z","phase":"Phase 1","brief_title":"SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma","source_id_and_acronym":"NCT05568680","lead_sponsor":"Verismo Therapeutics","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SynKIR-110"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/30/2023","start_date":" 03/30/2023","primary_txt":" Primary completion: 03/15/2026","primary_completion_date":" 03/15/2026","study_txt":" Completion: 03/30/2026","study_completion_date":" 03/30/2026","last_update_posted":"2024-05-16"},{"id":"9d99d61b-3750-4ca3-9c05-3d81abc8c4b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05617755","created_at":"2022-11-15T14:56:57.758Z","updated_at":"2024-07-02T16:35:05.607Z","phase":"Phase 1","brief_title":"AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05617755","lead_sponsor":"Arsenal Biosciences, Inc.","biomarkers":" BRCA1 • BRCA2 • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • AB-1015"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/29/2022","start_date":" 11/29/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-05-07"},{"id":"430c3067-053f-432e-8dd9-54e297aab048","acronym":"","url":"https://clinicaltrials.gov/study/NCT04577326","created_at":"2021-01-29T07:21:30.020Z","updated_at":"2024-07-02T16:35:06.711Z","phase":"Phase 1","brief_title":"Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma","source_id_and_acronym":"NCT04577326","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • ATA2271 • cyclophosphamide intravenous • engineered autologous T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/30/2020","start_date":" 09/30/2020","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-05-01"},{"id":"22ffb21f-989e-4653-87ef-38c78fadff5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03054298","created_at":"2021-01-18T15:02:34.204Z","updated_at":"2024-07-02T16:35:22.364Z","phase":"Phase 1","brief_title":"CAR T Cells in Mesothelin Expressing Cancers","source_id_and_acronym":"NCT03054298","lead_sponsor":"University of Pennsylvania","biomarkers":" PD-L1","pipe":" | ","alterations":" MSLN expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TmMSTN-01"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 04/06/2017","start_date":" 04/06/2017","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-01-24"},{"id":"3be9f507-67a2-4cb7-a07b-b039d2c87116","acronym":"","url":"https://clinicaltrials.gov/study/NCT05164666","created_at":"2021-12-21T16:53:48.131Z","updated_at":"2024-07-02T16:35:25.177Z","phase":"Phase 1","brief_title":"A Study of TAK-103 in Adult With Solid Tumors","source_id_and_acronym":"NCT05164666","lead_sponsor":"Takeda","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NIB103"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2","initiation":"Initiation: 01/05/2022","start_date":" 01/05/2022","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2023-12-27"},{"id":"89c725c9-e95c-4a50-a2e0-56a79f7ec50f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05372692","created_at":"2022-05-13T12:54:25.449Z","updated_at":"2024-07-02T16:35:42.810Z","phase":"","brief_title":"Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer","source_id_and_acronym":"NCT05372692","lead_sponsor":"Weijia Fang, MD","biomarkers":" MSLN","pipe":"","alterations":" ","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LD013"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 04/12/2022","start_date":" 04/12/2022","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 02/01/2023","study_completion_date":" 02/01/2023","last_update_posted":"2023-07-17"},{"id":"f8a952e4-5c1e-4c1d-b24f-75b41328f45f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05089266","created_at":"2021-10-22T12:53:00.028Z","updated_at":"2024-07-02T16:35:42.867Z","phase":"Phase 1","brief_title":"Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors","source_id_and_acronym":"NCT05089266","lead_sponsor":"Shanghai Cell Therapy Group Co.,Ltd","biomarkers":" PD-L1 • MSLN","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BZDS1901"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/30/2021","start_date":" 11/30/2021","primary_txt":" Primary completion: 07/30/2024","primary_completion_date":" 07/30/2024","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2023-07-17"},{"id":"26dd7949-9dd6-4b50-b524-f82cd6d11b0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05944185","created_at":"2023-07-13T18:10:50.357Z","updated_at":"2024-07-02T16:35:42.965Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors","source_id_and_acronym":"NCT05944185","lead_sponsor":"Shanghai Cell Therapy Group Co.,Ltd","biomarkers":" PD-L1 • MSLN","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BZDS1901"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2023-07-14"},{"id":"355168ac-10dc-49c7-8139-2017041e1380","acronym":"","url":"https://clinicaltrials.gov/study/NCT05848999","created_at":"2023-05-08T15:04:06.615Z","updated_at":"2024-07-02T16:35:48.189Z","phase":"Phase 1","brief_title":"UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05848999","lead_sponsor":"Zhejiang University","biomarkers":" IL6 • MSLN • IL10","pipe":"","alterations":" ","tags":["IL6 • MSLN • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • UCLM802"],"overall_status":"Recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 04/27/2023","start_date":" 04/27/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-05-12"},{"id":"b002053e-8556-4fa5-82ed-3d2c05fde55e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05783089","created_at":"2023-03-24T16:04:11.215Z","updated_at":"2024-07-02T16:35:52.329Z","phase":"Phase 1","brief_title":"MSLN-targeted CAR-T Cells in Solid Tumors.","source_id_and_acronym":"NCT05783089","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" IL6 • MSLN • IL10","pipe":"","alterations":" ","tags":["IL6 • MSLN • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UCLM802"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2023-03-24"},{"id":"00f6bf90-3a08-455d-82d2-2ccde3366ae0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05775666","created_at":"2023-03-20T20:03:30.879Z","updated_at":"2024-07-02T16:35:52.909Z","phase":"Phase 1","brief_title":"UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05775666","lead_sponsor":"Peking University","biomarkers":" IL6 • MSLN • IL10","pipe":"","alterations":" ","tags":["IL6 • MSLN • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • UCLM802"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-03-20"},{"id":"62e81424-45a7-4f78-9a1d-1eea6fabca98","acronym":"","url":"https://clinicaltrials.gov/study/NCT05531708","created_at":"2022-09-08T14:56:13.081Z","updated_at":"2024-07-02T16:35:54.417Z","phase":"Phase 1","brief_title":"Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT05531708","lead_sponsor":"Shanghai Pudong Hospital","biomarkers":" MSLN","pipe":"","alterations":" ","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • UCLM802"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/02/2021","start_date":" 04/02/2021","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2023-03-01"},{"id":"0e2c53e2-5daa-4613-9cf4-4a3a1038b338","acronym":"","url":"https://clinicaltrials.gov/study/NCT03198052","created_at":"2021-01-18T15:46:10.109Z","updated_at":"2024-07-02T16:35:55.664Z","phase":"Phase 1","brief_title":"GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers","source_id_and_acronym":"NCT03198052","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA","pipe":" | ","alterations":" MSLN expression • EGFR positive • GPC3 expression","tags":["EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • EGFR positive • GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-02-14"},{"id":"8be2ee14-5e35-4a28-8a6d-71e0e53b1c4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05373147","created_at":"2022-05-13T12:54:33.660Z","updated_at":"2024-07-02T16:36:01.813Z","phase":"Phase 1","brief_title":"αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors","source_id_and_acronym":"NCT05373147","lead_sponsor":"Shanghai Mengchao Cancer Hospital","biomarkers":" PD-L1 • PD-1 • IL6 • MSLN • IL2 • IL10","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1 • IL6 • MSLN • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BZDS1901"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 10/30/2020","start_date":" 10/30/2020","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 08/01/2023","study_completion_date":" 08/01/2023","last_update_posted":"2022-10-26"},{"id":"5680e6c0-6a5a-4e90-aaac-028889578a1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05141253","created_at":"2021-12-02T18:54:25.304Z","updated_at":"2024-07-02T16:36:11.366Z","phase":"Phase 1","brief_title":"Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors","source_id_and_acronym":"NCT05141253","lead_sponsor":"Tongji Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RD133"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 01/12/2022","start_date":" 01/12/2022","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2036","study_completion_date":" 11/01/2036","last_update_posted":"2022-04-27"},{"id":"4465b15f-e650-40db-95ec-d8d83a386576","acronym":"","url":"https://clinicaltrials.gov/study/NCT05344976","created_at":"2022-04-25T21:58:14.342Z","updated_at":"2024-07-02T16:36:11.525Z","phase":"Phase 1","brief_title":"MSLN STAR-T Cells in the Treatment of Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05344976","lead_sponsor":"Peking University","biomarkers":" EGFR • ALK • MET • ROS1 • MSLN","pipe":" | ","alterations":" ALK positive • EGFR positive • EGFR negative • MSLN positive","tags":["EGFR • ALK • MET • ROS1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • EGFR positive • EGFR negative • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YTS105"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 04/14/2022","start_date":" 04/14/2022","primary_txt":" Primary completion: 10/14/2024","primary_completion_date":" 10/14/2024","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2022-04-25"},{"id":"2d23aab4-1f16-4ace-937a-0b431ccf7367","acronym":"","url":"https://clinicaltrials.gov/study/NCT05166070","created_at":"2021-12-21T15:53:43.976Z","updated_at":"2024-07-02T16:36:19.299Z","phase":"Phase 1","brief_title":"An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors","source_id_and_acronym":"NCT05166070","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RD133"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 01/01/2037","study_completion_date":" 01/01/2037","last_update_posted":"2021-12-21"},{"id":"c57218fe-9186-4e3a-b510-e014a45f68cf","acronym":"Amaretto","url":"https://clinicaltrials.gov/study/NCT04981691","created_at":"2021-07-29T14:53:07.374Z","updated_at":"2024-07-02T16:36:24.273Z","phase":"Phase 1","brief_title":"Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT04981691 - Amaretto","lead_sponsor":"Ruijin Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • MSLN CAR-T • UCLM802"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 01/09/2022","primary_completion_date":" 01/09/2022","study_txt":" Completion: 07/09/2022","study_completion_date":" 07/09/2022","last_update_posted":"2021-09-17"},{"id":"046bd970-a819-491c-b309-6d96f8ea30b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03941626","created_at":"2021-01-19T18:01:10.172Z","updated_at":"2024-07-02T16:36:35.027Z","phase":"Phase 1/2","brief_title":"Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies","source_id_and_acronym":"NCT03941626","lead_sponsor":"Shenzhen BinDeBio Ltd.","biomarkers":" HLA-A • MSLN • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • MSLN positive • HLA-A positive","tags":["HLA-A • MSLN • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • MSLN positive • HLA-A positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • multi-target gene-modified CAR-T/TCR-T cell immunotherapy"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2021-02-04"},{"id":"864e20df-a59c-41cd-b490-615021eb2ec2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03545815","created_at":"2021-01-18T17:27:27.742Z","updated_at":"2024-07-02T16:36:42.187Z","phase":"Phase 1","brief_title":"Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.","source_id_and_acronym":"NCT03545815","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GC008t • MPTK-CAR-T cells • MSLN CAR-T"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 03/19/2018","start_date":" 03/19/2018","primary_txt":" Primary completion: 10/30/2020","primary_completion_date":" 10/30/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2020-08-10"},{"id":"310da539-a784-44b1-83d7-d9346d60eb33","acronym":"","url":"https://clinicaltrials.gov/study/NCT04503980","created_at":"2021-01-18T21:35:54.015Z","updated_at":"2024-07-02T16:36:42.230Z","phase":"Phase 1","brief_title":"αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors","source_id_and_acronym":"NCT04503980","lead_sponsor":"Shanghai Cell Therapy Group Co.,Ltd","biomarkers":" PD-L1 • MSLN","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BZDS1901"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/26/2020","start_date":" 03/26/2020","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2020-08-07"},{"id":"1a05a158-2b35-483a-8c45-2aa44e439674","acronym":"","url":"https://clinicaltrials.gov/study/NCT04489862","created_at":"2021-01-18T21:34:24.718Z","updated_at":"2024-07-02T16:36:42.681Z","phase":"Phase 1","brief_title":"αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors","source_id_and_acronym":"NCT04489862","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" PD-L1 • MSLN","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BZDS1901"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 05/13/2020","start_date":" 05/13/2020","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-07-28"}]